Business
Pelthos Therapeutics Expands Board of Directors with the Appointment of Andrew Einhorn
Seasoned executive brings four decades of finance, capital markets, and life sciences experienceDURHAM, N.C., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced it has named veteran finance executive Andrew J. Einhorn to its Board of Directors effective immediately. Mr. Einhorn will serve on the Board of Directors until Pelt
About this update from Pelthos Therapeutics Inc.
[{"type":"image","alt":"Pelthos Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Pelthos Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":179,"url":"https://media.zenfs.com/en/globenewswire.com/f94dd4c648565b20de109cac2516c355"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/yWW833l91CiuD7s17uRPhw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI1MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f94dd4c648565b20de109cac2516c355","width":300,"height":179}},"lazy":false},{"type":"text","content":"Seasoned executive brings four decades of finance, capital markets, and life sciences experience","length":96,"tagName":"p"},{"type":"text","content":"DURHAM, N.C., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced it has named veteran finance executive Andrew J. Einhorn to its Board of Directors effective immediately. Mr. Einhorn will serve on the Board of Directors until Pelthos’ 2026 annual meeting of shareholders and until his successor is elected and qualified or until his earlier resignation or removal. Also, effective immediately, Mr. Einhorn will also serve on the Audit Committee and the Compensation Committee of the Pelthos Board of Directors.","length":684,"tagName":"p"},{"type":"text","content":"Mr. Einhorn brings extensive corporate financial management experience to the role, with more than four decades of experience in investment banking and capital markets, as well as in C-level finance roles at fast-paced clinical and commercial-stage life science companies.","length":272,"tagName":"p"},{"type":"text","content":"“Andrew’s extensive capital markets and in-house finance experience make him a strong addition to the Pelthos Board of Directors,” said Peter Greenleaf, Chairman of the Board. “His experience accelerating company growth at multiple public and private life science companies will be critical as Pelthos grows as a commercially focused company.”","length":343,"tagName":"p"},{"type":"text","content":"With the addition of Mr. Einhorn, the Pelthos Board has increased to eight directors.","length":85,"tagName":"p"},{"type":"text","content":"Mr. Einhorn currently serves as a consultant at Danforth Advisors, p...